Skip to main content
SpringerLink
Log in

Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Recent reports suggest that elevated levels of plasminogen activator inhibitor-1 (PAI-1) may contribute to tumour progression. The studies reported here were designed to help elucidate PAI-1's contribution to the invasive and migratory phenotype. Antibodies to PAI-1 dose-dependently, and significantly, inhibited the invasive and migratory potential of human HT1080 fibrosarcoma cells, as did an antibody to uPA and the plasmin inhibitor aprotinin. Invasion of the human melanoma cell line, BLM, was also attenuated by the anti-PAI-1 monoclonal antibody MAI-12. The non-invasive human melanoma cell line, IF6, which does not express uPA, provided further confirmation of PAI-1 and uPA's role as, upon transfection with uPA, this cell line attained an invasive phenotype, which was again attenuated by MAI- 12. Although antibodies to PAI-1 did not affect the adhesion of HT1080 cells to vitronectin, the antibody to uPA reduced their attachment. Addition of exogenous PAI-1, however, prevented HT1080 cell adhesion (IC50 180nM) and promoted cell detachment from vitronectin. Furthermore melanoma cells transfected with a uPA variant, which had an impaired interaction with PAI-1, were not invasive and had impaired binding to vitronectin. These data highlight the importance of a balanced proteolysis and suggest an additional role for PAI-1 distinct from its role in proteolysis. These data also suggest that uPA and PAI-1 may co-operate in the migratory process by respectively facilitating the attachment to, and subsequent detachment from, vitronectin in the extracellular matrix. These results support the clinical findings and indicate that modulation of PAI-1 activity may be of therapeutic benefit for the treatment of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumour growth, invasion and metastasis. Cell Mol Life Sci 2000; 57: 25–40.

    Article  PubMed  CAS  Google Scholar 

  2. Schmitt M, Wilhelm OG, Reuning U et al. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis and Proteolysis 2000; 14: 114–32.

    Article  CAS  Google Scholar 

  3. Noël A, Bajou K, Masson V et al. Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1. Fibrinolysis and Proteolysis 2000; 13: 220–5.

    Article  Google Scholar 

  4. Foekens JA, Schmitt M, Van Putten WL et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12(8): 1648–58.

    PubMed  CAS  Google Scholar 

  5. Quax PH, Van Muijen GN, Weening-Verhoeff et al. Metastatic behaviour of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 1991; 115(1): 191–9.

    Article  PubMed  CAS  Google Scholar 

  6. Liu G, Shuman MA, Cohen RL. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 1995; 60(4): 501–6.

    PubMed  CAS  Google Scholar 

  7. Tsuchiya H, Katsuo S, Matsuda E et al. The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice. Gen Diagn Pathol 1995; 141(1): 41–8.

    PubMed  CAS  Google Scholar 

  8. Frandsen TL, Stephens RW, Declerk PJ et al. Blocking PAI-1 function inhibits metastasis formation from human breast cancer xenograft in nude mice. Proc Am Assoc Cancer Res 1999; 40: 452.

    Google Scholar 

  9. Bajou K, Noel A, Gerard RD et al. Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vascularization. Nat Med 1998; 4(8): 923–8.

    Article  PubMed  CAS  Google Scholar 

  10. Verheijen JH, Caspers MPM, Chang GTG et al. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 1986; 5: 3525–30.

    PubMed  CAS  Google Scholar 

  11. Bakker AHF, Van de Greef W, Rehberg EF et al. Introduction of lysine and clot binding properties in the kringle one domain of tissue-type plasminogen activator. J Biol Chem 1993; 268: 18496–501.

    PubMed  CAS  Google Scholar 

  12. Jones DH, Howard BH. A rapid method for site-specific mutagenesis and directional subcloning by using the polymerase chain reaction to generate recombinant circles. Biotechniques 1990; 8: 178–83.

    PubMed  CAS  Google Scholar 

  13. Bakker AHF, Nieuwenbroek NME, Verheijen JH. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator. Protein Eng 1995; 12: 1295–302.

    Google Scholar 

  14. Verheijen JH, Nieuwenbroek NME, Beekman B et al. Modified proenzymes as artificial substrates for proteolytic enzymes: Colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem J 1997; 323: 603–9.

    PubMed  CAS  Google Scholar 

  15. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–5.

    Article  PubMed  CAS  Google Scholar 

  16. Granelli-Piperno A, Reich E. Plasminogen activators of the pituitary gland enzyme: characterization and hormonal modulation. J Exp Med 1978; 148: 223–34.

    Article  PubMed  CAS  Google Scholar 

  17. Verheijen JH, Mullaart E, Chang GTG et al. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48: 266–9.

    PubMed  CAS  Google Scholar 

  18. Thorsen S, Philips M, Selmer J et al. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen activator inhibitor type 1 and type 2. Eur J Biochem 1988; 175: 33–9.

    Article  PubMed  CAS  Google Scholar 

  19. Kemperman H, Wijnands YM, Roos E. Alpha V Integrins on HT-29 colon carcinoma cells: adhesion to fibronectin is mediated solely by small amounts of alpha V beta 6, and alpha V beta 5 is co-distributed with actin fibres. Exp Cell Res 1997; 234: 156–64.

    Article  PubMed  CAS  Google Scholar 

  20. Holst-Hansen C, Johannessen B, Høyer-Hansen G et al. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 1996; 14(3): 297–307.

    PubMed  CAS  Google Scholar 

  21. Eitzman D, Krauss J, Shen T et al. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 1996; 87(11): 4718–22.

    PubMed  CAS  Google Scholar 

  22. Soff GA, Sanderowitz J, Gately S et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumour growth, tumour-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995; 96(6): 2593–600.

    PubMed  CAS  Google Scholar 

  23. Andreasen PA, Kjøller L, Christensen L et al. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997; 72(1): 1–22.

    Article  PubMed  CAS  Google Scholar 

  24. Kost C, Stuber W, Ehrlich HJ et al. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem 1992; 267(17): 12098–105.

    PubMed  CAS  Google Scholar 

  25. Kjøller L, Kanse SM, Kirkegaard T et al. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232(2): 420–9.

    Article  PubMed  Google Scholar 

  26. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997; 18(9): 415–7.

    Article  PubMed  CAS  Google Scholar 

  27. Neumeier R, Reutter W. Hepatocyte adhesion on plastic. Different mechanisms for serum-and fibronectin-mediated adhesion. Exp Cell Res 1985; 160(2): 287–96.

    Article  PubMed  CAS  Google Scholar 

  28. Steele JG, Johnson G, Norris WD et al. Adhesion and growth of cultured human endothelial cells on perfluorosulphonate: Role of vitronectin and fibronectin in cell attachment. Biomaterials 1991; 12(6): 531–9.

    Article  Google Scholar 

  29. Steele JG, Johnson G, Underwood PA. Role of serum vitronectin and fibronectin in adhesion of fibroblasts following seeding onto tissue culture polystyrene. J Biomed Mater Res 1992; 26(7): 861–84.

    Article  PubMed  CAS  Google Scholar 

  30. Germer M, Kanse SM, Kirkegaard T et al. Kinetic analysis of integrindependent cell adhesion on vitronectin-the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. Eur J Biochem 1998; 253(3): 669–74.

    Article  PubMed  CAS  Google Scholar 

  31. Kanse SM, Kost C, Wilhelm OG et al. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996; 224(2): 344–53.

    Article  PubMed  CAS  Google Scholar 

  32. Waltz DA, Natkin LR, Fujita RM et al. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997; 100(1): 58–67.

    Article  PubMed  CAS  Google Scholar 

  33. Deng G, Royle G, Seiffert D et al. The PAI-1/vitronectin interaction: Two cats in a bag? Thromb Haemost 1995; 74(1): 66–70.

    PubMed  CAS  Google Scholar 

  34. Bacharach E, Itin A, Keshet E. In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci USA 1992; 89(22): 10686–90.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Xenova Group plc, Slough, UK

    Teresa D. Brooks, Marilyn T. Spencer & Peter A. Charlton

  2. Gaubius Laboratory TNO-PG, Leiden, The Netherlands

    Jennita Slomp, Paul H.A. Quax, Anton C.W. De Bart & Jan H. Verheijen

Authors
  1. Teresa D. Brooks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennita Slomp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul H.A. Quax
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anton C.W. De Bart
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marilyn T. Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jan H. Verheijen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peter A. Charlton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brooks, T.D., Slomp, J., Quax, P.H. et al. Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro . Clin Exp Metastasis 18, 445–453 (2000). https://doi.org/10.1023/A:1011882421528

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011882421528

Search

Navigation